News Hub | News Direct

ALDERHEY@NYWHERE™ CREATING A HOSPITAL OF THE FUTURE: “A HOSPITAL WITHOUT WALLS”

AlderHey Innovation / i5 Media

ALDER HEY LAUNCHES GROUND-BREAKING HYBRID DIGITAL HEALTH PLATFORM IN COLLABORATION WITH MICROSOFT AND MINDWAVE. “TODAY’S CHILD, TOMORROW’S HEALTHIER ADULT” Alder Hey Children’s NHS Foundation Trust, one of the world’s leading paediatric healthcare institutions, has today launched a ground-breaking digital platform that is set to revolutionise the way in which patient care is delivered to children and young people. The hybrid health platform AlderHey@nywhere™ is being championed as a “hospital of the future”, where patient and clinical care is delivered in a hybrid world, both physical and virtual, to create a “hospital without walls”. The interactive and immersive digital platform provides a hybrid point of access and patient care for families, children, young people and clinicians to manage, treat, educate and coordinate delivery of their healthcare. Most importantly, it will focus on preventative healthcare and will make patient care more accessible and personalised. https://www.alderheyinnovation.com/alderheyanywhere The technology was developed by Alder Hey Innovation in collaboration with Microsoft and Mindwave as a solution to addressing the finite capacity of hospital and community resources, including both physical space and workforce. This was also paired with an increased demand of accident and emergency admissions, long waiting times for outpatient appointments, and increasing lengths of stay. Alder Hey has a dedicated innovation centre within the hospital and campus, focused on using cutting-edge technologies and innovations to solve the real-world, day-to-day problems faced by children and young people. Alder Hey Innovation believes that by leveraging innovative health tech, digital platforms, data and AI, it can revolutionise the way healthcare is delivered to children and young people. It seeks to break down the traditional barriers for patients when accessing care and personal health information, as well as when receiving therapies and seeking education, creating a future of healthcare that is a “hospital without walls ” with the focus of care being the individual, taking a more personalised and tailored approach. Commenting on the launch of the new digital health platform, Managing Director of Alder Hey Innovation, Claire Liddy, said: “At the moment, healthcare is most often about treating people that are ill. What we want to do is to shift to a more preventative model of care that is individualised and tailored and that empowers children and young people to take ownership of their healthcare and treatment. There are so many different technologies out there now, including wearable technology and devices such as smartwatches that enable you to monitor your health at home. What we needed was a hybrid platform to bring it all together into one place so that families, children and young people could access it, alongside their clinicians at the hospital. “We think the AlderHey@nywhere™ platform will allow us to elevate the level and access to care for children and young people who tell us that they want to be empowered to understand and manage their own healthcare and treatment. It also allows us to move to a more preventative healthcare modelling, making healthcare more individual and personalised.” AlderHey@nywhere™ is a co-development with Microsoft and tech SME Mindwave. The collaboration came together to co-create a hybrid healthcare platform that will create a way of delivering healthcare for children and young people that is far more tailored to the individual, giving them better life chances. Claire Liddy added: “The Innovation Centre at Alder Hey Children’s hospital is a really special and unique place. It’s a dedicated team, all focussed on bringing new technology into healthcare for the benefit of children and young people. We work with a wide range of private sector partners, including tech giants, SMEs, entrepreneurs and universities, to co-invent new technologies and innovations. We have a different mindset and culture of innovation; we are able to move fast and think big, which allows our innovation path to accelerate much faster than the traditional pathways. We are able to fuse healthcare and tech innovation with industry. This fusion brings something special and unique, creating faster-paced technologies.” AlderHey@nywhere™ provides a unique digital platform that is designed with children young people and their families in mind, making it visually aesthetic, engaging and immersive, but also intuitive. At the same time, its dual purpose is engineered for clinicians to monitor, assess and optimise data and clinical workflow in the management and delivery of patient care. Mindwave – which has previously worked with Alder Hey to develop other tech platforms, including AlderPlay and mental health platform CYP As One™ – have been the lead developers on the visual interface of the portal, as well as the interconnectivity and operability of data. Founder and CEO, Kumar Jacob, said: “It has been a privilege to work with Alder Hey Innovation Centre and Microsoft to be responsible for the design and development of the user interface (UI) and user experience (UX) of AlderHey@nywhere™. Our role has been to ensure that the portal is visually appealing and immersive, making sure the experience that young people, children and their families have is engaging, enjoyable, simple-to-use and easy-to-understand. At the same time, we want the complicated data and AI to flow seamlessly to ensure that the data flow of information is interoperable and sent across multiple devices, making the experience seamless, functional and easy for clinicians to use.” AlderHey@nywhere™ enables the interoperability of multiple systems using FHIR, remote devices and resources for management of acute and chronic conditions. Furthermore, it collates a new unique data set for longer-term, AI-augmented decision-making for preventative intervention, personalised care and long-term disease prevention. Umang Patel, Chief Clinical Information Officer at Microsoft, also offers a unique perspective thanks to his dual role at Microsoft and as a paediatrician working in the NHS at Frimley Park Hospital. "It's been a real privilege to work with Alder Hey to develop the AlderHey@nywhere™ platform," he says. "Microsoft always loves projects that gets its staff excited - to be given the opportunity to help children and young people - was one such project. Hopefully we have been able to bring some new insights, skills and innovations that will help Alder Hey not only solve problems locally but scale beyond the Liverpool region. What they have done at Alder Hey is great for many reasons, but two stand out: first, the Alder Hey team has managed to keep it simple. If you ask 100 doctors what they want in an ideal system, they will tell you a million important things. The team has managed to scale that back, kept it usable, and brought the most important things to the front. Second, is the momentum they have generated- it's trailblazing innovation at its best.” AlderHey@nywhere™ was based around a model of prevention and intervention. The digital health platform allows for: A true hybrid of both physical and virtual patient care Remote real-time monitoring of patient care for intervention Creating a platform of care that is tailored and self-managed Digital Bio-markers and IoMT for preventive real time augmented clinical decision making Children and young people want to be empowered to engaged interactively with gamification to understand and manage their care To download our images for AlderHey @nywhere image assets available here https://we.tl/t-IYVZFHiWwj ABOUT US ABOUT ALDER HEY INNOVATION CENTRE – Todays Child, Tomorrows Healthier Adult Alder Hey Innovation is the largest, dedicated, purpose built, hospital led innovation centre in the UK. Alder Hey Children’s NHS Trust has a proud history of innovation spanning over a hundred years. Today we continue that legacy pioneering the use of cutting-edge technology and innovating to save lives and improve the life chances of today’s child. Our ambition is to be the world leader in advancing child health with innovation, utilising our unique hospital-based innovation centre, disrupting, discovering and disseminating to have real impact. Our mission is to solve the real-world healthcare problems children and young people face today, creating fair access to care and enabling a healthier future for all. Our unique strengths lie in our experience to innovate and disrupt, with a strong track record of rapid problem solving, creating an end-to-end pipeline and process from problem identification and solutions through to commercial income. Our strategy is fueled by a bespoke open innovation system, to rapidly identify real-world problems and bring the right partners together to solve those with innovative and disruptive technology. Our co creation approach involves scouting and partnering with local and international industry and academia, bringing the most innovative technology and solutions to Alder Hey, where we strive for excellence and breakthroughs in healthcare. www.alderheyinnovation.com ABOUT ALDER HEY Alder Hey Children’s NHS Foundation Trust provides care for over 330,000 children and young people every year. Alder Hey delivers clinical excellence for all children, for routine illnesses as well as very complex and rare conditions. One of four stand-alone children’s hospitals in the UK, it is a national centre for neuro and craniofacial surgery, a regional centre for burns injuries and a Centre of Excellence for children with cancer, heart, spinal and brain disease. Alder Hey as an NIHR funded Clinical Research Facility (CRF) that specialises in the design, and delivery, of early phase drug trials in children with a wide range of conditions. The Trust is one of only four epilepsy surgical centres in the UK and one of only two accredited major trauma centres in the North West. Alder Hey is also a respiratory Extracorporeal Membrane Oxygenation (ECMO) surge centre and is the referral centre for the treatment of congenital heart defects in North West England, North Wales and Isle of Man. It became the first UK Centre of Excellence for Childhood Lupus in 2010. Alder Hey is the first accredited Investing in Children hospital in the UK. It has a dedicated patient experience programme which includes the award-winning Alder Hey Arts involving music therapy, dance programmes, storytelling and animation projects. It is also one of a few hospitals to have a Children and Young Person’s Forum. Alder Hey opened a new hospital ‘Alder Hey in the Park’ in 2015. Europe’s first hospital in a park, the new facility provides a purpose-built, unique and world class healing environment for children and young people. Alder Hey is supported by The Alder Hey Children’s Charity which aims to raise vital funds for lifesaving equipment, research projects and patient experience initiatives. For more information visit www.alderhey.nhs.uk and www.alderheycharity.org ABOUT MINDWAVE Mindwave (Mindwave Ventures Limited) designs and develops digital applications for healthcare. Mindwave works with NHS organisations, charities and universities to help them develop innovative digital products to deliver healthcare and carry out health research. Mindwave's patient portal is currently deployed in over eight organisations. The company has grown to around 95 staff based in the UK and Pondicherry (South India). Mindwave's designers based in the UK are steeped in user centred design. Design and development follows Government Digital Service (GDS) guidelines and Agile principles. Born out of the NIHR Maudsley Biomedical Research Centre (BRC), Mindwave was founded in 2014; the brain-child of Kumar Jacob MBE, who trained as an accountant and then operated in different guises across a broad range of sectors, including charity, education, health and technology. Having worked with creative teams that brought out hugely popular video games such as Burnout, Singstar, WipeOut at Criterion and Sony, whilst also serving as a non-exec director at SLaM and as the chair at the Maudsley Charity, Kumar could see a disparity between the way that the public sector and the technology sector were solving problems. Enter Mindwave. Over the years, the team has grown from a handful of designers to a full-service provider, supplying expert health design and technology consultancy alongside end-to-end digital service development. To date, Mindwave has worked with a wide range of health focused organisations, including multiple NHS trusts and ICS regions, health focused charities, and a large number of clinical academic teams. Mindwave also works with and supports a number of health-tech startups, providing consultancy, design, development and project management to support peers to successfully enter the market. Mindwave is known for going above and beyond, and for the team’s eagerness to help, converse and collaborate. www.mindwaveventures.com Contact Details Alder Hey Innovation /i5 Media Gerard Franklin gerard@i5media.co.uk

June 10, 2022 02:15 AM Eastern Daylight Time

New Survey Shows the Next Generation Embraces Remote Work for College to Career Transition

Velocity Global

Seven out of ten U.S. college-aged adults are likely to consider an entirely remote job One out of four never expect to hold a traditional 9-to-5 office job, and 85% see themselves holding a side gig Nine out of ten express anxiety about entering the workforce A survey released today by Velocity Global, the leading provider of global talent solutions, shows that U.S. college-aged adults embrace remote work in their career transition plans. The College to Career Survey examined 1,000 college-aged respondents’ attitudes on remote work and their work-life balance expectations as they prepare to transition into the workforce. “The next generation wants to work remotely, balance their ‘personal’ and ‘work’ lives, and prioritize flexibility and mental well-being. Companies should take notice: The old way of doing business is over,” said Sarah Fern, chief people officer at Velocity Global. “Put simply, students want the flexibility to work with anyone, anywhere, anytime, and they expect employers to meet them where they are.” Key findings on remote work: 69% of respondents are somewhat or extremely likely to consider a job that is entirely remote 80% of students would consider taking less money for their job if it allowed a remote option The majority (57%) say being remote increases their productivity Nine out of ten respondents report work-life balance as being either the most important factor (53%) or a somewhat important factor (37%) in selecting a career Fewer than 1 in 5 (18%) say they prefer to work from an office five days per week Fewer than half (44%) of respondents plan to have a traditional (Monday-Friday, 9-to-5) in-person job, and 1 out of 4 (23%) never expect to hold a traditional office job Impacts on emotional well-being: The survey also found a large impact on the emotional well-being of respondents as a result of the move to remote work and learning over the last several years. 56% of respondents acknowledged remote work/study negatively impacted their mental health “a lot” (14%) or “somewhat” (42%) 86% reported a high level of stress or anxiety about entering the workforce, including 35% who indicated they are “very” anxious about entering the workforce, and an additional 51% said they are “somewhat” anxious about doing so Participation in the gig economy: An overwhelming majority of students intend to supplement their primary job with a side gig. 85% of respondents said they either definitely (27%) or possibly (58%) expect to have a side gig in addition to their primary job “That number is staggering, and the C-suite needs to harness the possibilities of tomorrow’s workforce who have varied interests, skills, and allegiances,” said Fern. “Talent is telling us how they will succeed, and it includes full-time, part-time, contract, and freelance work - and sometimes a combination of these. It is entirely possible for you to get the best from your talent while they also pursue other interests. It works for both of you.” International results: The survey also gathered input from 500 students and recent graduates in the United Kingdom (U.K.) and 500 in Brazil, with very similar results. 72% in the U.K. said they would consider an entirely remote position, and a staggering 85% in Brazil say the same 84% of respondents in the U.K. and 82% in Brazil said they would be willing to consider a position that paid less money if it offered the flexibility to work from anywhere “These trends with college students and recent graduates in the U.S. are mirrored in other parts of the world, highlighting the accessibility of a global workforce. In the U.K. and Brazil — where Velocity Global clients increasingly seek supported talent — work flexibility is seen as one of the most compelling factors considered when entering the job market,” said Fern. Methodology: This survey was conducted on behalf of Velocity Global by Rep Data. All selected samples were subjected to stringent quality control standards, including technological controls such as automatic geographical IP detection, tracking and deduplication, open-end pre-screening, and re-captchas. Rep Data sourced multiple suppliers to ensure a representative sample, each supplier possessing its own unique recruitment model and incentive structure, which increased sample source diversity and quality. About Velocity Global Velocity Global accelerates the future of work for anyone, anywhere, anyhow. Its Global Work Platform TM simplifies the employer and talent experience through its proprietary cloud-based talent management technology, backed by personalized expertise and unmatched global scale. The platform offers a full suite of talent solutions, including global Employer of Record and Contractor Management, to help companies onboard, manage, and pay talent in more than 185 countries and all 50 United States. Thousands of brands rely on Velocity Global to build international teams without the cost or complexity of setting up foreign legal entities or state registrations. Velocity Global was named a "Leader" in Global Employer of Record Services by prominent analyst firm NelsonHall. Founded in 2014, the company has hundreds of employees across six continents. For more information, visit velocityglobal.com. Contact Details Velocity Global Chris McGrath +1 720-650-4348 news@velocityglobal.com Company Website https://velocityglobal.com/

June 09, 2022 07:00 AM Mountain Daylight Time

Video Image

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Quidel Corporation

With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rapid point-of-care diagnostic Lyme disease test. In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series. “The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field while expanding education and awareness programs for the public and physicians. We’re honored to have this collaborative partnership.” As part of its collaboration, Quidel will serve as sponsor for GLA’s Lyme awareness month as well as a series of educational PACE-accredited webinars. These events provide new information on various Lyme topics in an open discussion format, all designed to bring awareness around the Lyme disease epidemic, with rapid ways to diagnose and treat it. In addition, Quidel will be a sponsor for the GLA Global Gala 2022, the organization’s premier fundraising event to be held in October. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities, and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

June 09, 2022 06:00 AM Pacific Daylight Time

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

1BusinessWorld

Sylvester Feddes, the Country President and Pharma Head of Novartis Colombia, joins the 2022 Leading Entrepreneurs of the World Conference to talk about leading diversity and inclusion in a virtual environment. At Novartis Colombia, Sylvester and his team use innovative science and technology to address some of society's most challenging healthcare issues by discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. The LEW Conference is one of the largest and most comprehensive entrepreneurial events in the world and features business presentations, digital interviews, discussions and roundtables with the world's leading entrepreneurs and business leaders. Register to attend the 2022 LEW Conference to watch the live session of Sylvester's presentation and to connect with him live at the event: https://events.zoom.us/e/view/_LwgIoXQQL2gA_LMBaozZA All news and content distribution in partnership with News Direct. About Novartis Novartis is a leading healthcare company providing solutions to the changing needs of patients. We use science-based innovation to address society's biggest health care challenges. We discover and develop advanced treatments and find new ways to ensure access to as many people as possible. Likewise, we seek to guarantee an effective return for those who invest time, resources and ideas in our company. Our goal is to improve global health. Through our business, we make an important contribution to society: we discover and develop innovative medicines. Novartis works hand in hand with others to help address some of the world's biggest health challenges. Novartis About Leading Entrepreneurs of the World As part of 1BusinessWorld, Leading Entrepreneurs of the World is one of the largest and most comprehensive entrepreneurial platforms and events in the world and features entrepreneurs, founders and business leaders presenting on cutting-edge topics and the latest industry developments. Leading Entrepreneurs of the World About 1BusinessWorld 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

June 08, 2022 06:17 PM Eastern Daylight Time

Image

Oakland Pharmacy Inc. Partners With Comcast Business to Improve Network Management, Security and Speeds

Comcast California

Comcast Business today announced that it is providing Oakland Pharmacy Inc. – a business of community pharmacies and clinic pharmacies in Oakland, California region – with SD-WAN on the ActiveCore SM SDN Platform, Ethernet Dedicated Internet (EDI) connections for its sites as well as Business VoiceEdge® services and a 4G LTE backup connection. The combination of solutions is helping the local healthcare business improve operating procedures for its employees from the pharmacy counter to the IT desk – ultimately helping to provide elevated services for its customers. For more than 35 years, Oakland Pharmacy Inc. has served residents in Alameda County, working diligently to improve the healthcare opportunities within its communities, in particular for underserved populations – like the Asian Pacific Islander community, children incarcerated in the Juvenile Justice system, people experiencing homelessness and mental health patients – who need special healthcare assistance. Staff across the company’s seven locations are often bilingual, speaking Spanish, Cantonese, Vietnamese or Mandarin to better connect with the different cultural backgrounds that the locations serve. As medical records continue to shift to the cloud, it has become increasingly important for the pharmacy industry to have fast, reliable and secure network connections capable of quickly pulling and sending patient information. “I am very happy with the quality of service we’ve received,” said Timothy Tam, IT specialist for Oakland Pharmacy Inc. “Now our employees can more rapidly adjudicate claims, e-fax and process new prescriptions without worrying about slow network speeds.” In addition to the fast and reliable EDI connections, SD-WAN on the ActiveCore SM SDN Platform helps to configure the business’ network, as well as proactively monitor for, and troubleshoot, connectivity issues across Oakland Pharmacy Inc.’s various locations. Meanwhile, the company’s 4G LTE backup connection is helping to build network redundancy while its Business VoiceEdge® solution is providing great call quality plus a web portal to help manage calls and voicemails. “Our local pharmacies are truly the bastions of our communities. They keep us healthy, whether it’s providing vaccines, medications or other consultation on healthcare best practices,” said Kristeen Cominiello, vice president of Comcast Business in California. “Comcast Business recognizes that connectivity is the key to ensuring that these services continue to reach community members in need, and is proud to offer its support to Oakland Pharmacy Inc.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company that connects people to moments that matter. We are principally focused on connectivity, aggregation, and streaming with 57 million customer relationships across the United States and Europe. We deliver broadband, wireless, and video through our Xfinity, Comcast Business, and Sky brands; create, distribute, and stream leading entertainment, sports, and news through Universal Filmed Entertainment Group, Universal Studio Group, Sky Studios, the NBC and Telemundo broadcast networks, multiple cable networks, Peacock, NBCUniversal News Group, NBC Sports, Sky News, and Sky Sports; and provide memorable experiences at Universal Parks and Resorts in the United States and Asia. Visit www.comcastcorporation.com for more information. Contact Details Adriana Arvizo +1 925-200-1919 Adriana_Arvizo@comcast.com

June 08, 2022 09:05 AM Pacific Daylight Time

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Kadimastem

If the feasibility study is successful, it would be a significant step forward towards pancreatic tissue engineering that could be used to develop Kadimastem’s IsletRx for diabetes in a way where transplantation would be possible without concern of immune rejection Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring other neurodegenerative diseases and developing a potential cure for diabetes, has signed an agreement with Implant Therapeutics, Inc. for use of “Immune Evasive Cell” iACT cells, (Which are implant cells that the immune system does not recognize as foreign to the body) Implant's breakthrough technology to prevent transplant rejection. Under the terms of the agreement, a feasibility study will be conducted to test if Implant Therapeutic’s iACT TM cells can provide a solution to the challenge of transplant immune protection and avoidance of rejection of Kadimastem’s IsletRx for diabetes. If so, Implant Therapeutics iACT TM cells could be a good cell source for Kadimastem to create its glucose sensing, insulin producing pancreatic cells, the basis for IsletRx, without the need of Immune protection or immunosuppression. The iACT TM “Immune Evasive” cell technology uses genetic modifications to cloak cells to be seen as part of the receiving body’s immune system and therefore are not rejected following transplantation. The success of the licensing feasibility study would be a significant step forward towards the potential to create pancreatic islet organoids, capable of producing insulin and glucagon as well as regulating blood glucose levels, that would not be rejected by the body. A successful evaluation may result in the licensing by Kadimastem of Implant Therapeutics’ technology. Kadimastem CEO Asaf Shiloni said, “This strategic agreement with Implant is the result of a long-term effort we have invested in bringing the innovative “Immune Evasive” cell technology to Kadimastem. The new capability takes us to the forefront of the race to develop diabetes care and will allow us to apply advanced technologies to create an optimal and ultimate solution to the central problem of protecting cells from the patient's own immune system. I welcome the move and hope that this technology will further advance the development of IsletRx, with the ultimate goal of improving the lives of the millions of people living with diabetes worldwide." About IsletRx IsletRx is a cell therapy treatment for diabetes, achieved by expanding the population of allogeneic stem cells differentiated into functioning insulin and glucagon producing and releasing pancreatic islet cells. The company then uses a proprietary technology to select the highest functioning cells, enrich them and then transplant them into the body. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. About Implant Therapeutics Implant Therapeutics is a subsidiary of panCELLa whose mission is to develop therapeutic products in the immunology and cell therapy space and to partner with other companies to develop novel products in areas of regenerative medicine. Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering human iPSC cells that incorporate failsafe, iACT, hypoimmunogenic and safe-harbor technologies. These iPSC cells are “Immune Evasive” and are an ideal choice for replacement strategies of many cell types combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. To learn more, visit www.implant-rx.com. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

June 08, 2022 07:00 AM Eastern Daylight Time

Image

Telos Blockchain Sponsors Unbound Now Gala

Telos Foundation

The Telos Foundation is proud to announce that it will be the official sponsor for the 2022 Unbound Now Gala happening on June 7th in Waco, Texas. Telos is firmly in favor of all that Unbound Now stands for and has accomplished as a non-profit organization and is pleased to support them as they continue to provide aid for humanity’s most vulnerable. Tuesday’s gala celebrates 10 years of Unbound Now’s work to end human trafficking in local communities and around the world. Telos believes that global ESG concerns such as human trafficking, an illicit practice that has more than tripled in the last decade, must be eradicated at all costs. Unbound Now is leading the effort to help save the victims from this heartless act. Founded in the United States in 2012, Unbound Now has grown substantially, launching in several locations worldwide, including Cambodia, Mongolia, Indonesia, South Africa, and various countries in Europe. While their operations vary from one city to the next, Unbound offers three main lines of effort: Prevention and Awareness: Unbound Now works to educate and empower youth, spread awareness through citywide outreaches and provide human-trafficking presentations to groups and organizations. Professional Training: Unbound Now provides training to equip all professionals to use their skills to identify and serve victims of human trafficking. Survivor Advocacy: Unbound Now advocates for victims and survivors by meeting immediate needs, supporting survivors and their families, and connecting each survivor with resources for his or her unique restoration journey. The values and principles of the Telos team are closely aligned with those of Unbound Now and looks forward to making its contribution to put an end to human trafficking - once and for all. About Telos Live since 2018, Telos Blockchain (ticker: TLOS) is an ESG compliant Layer 1 smart contract platform that offers full-service compatibility with Solidity, Vyper and Native C++ smart contracts. The chain along with all of its departments operates at Net Zero status and offers the use of its fair smart contract powered governance system to any interested organization in modular fashion. The chain is capable of finalizing over a billion low-fixed-cost (w/ a feeless option) transactions per day. Since the launch of mainnet, Telos has operated with a flawless network uptime record. The validators of the network are globally decentralized, vetted (KYC) and are all equitable in size. Telos is one of the only Layer 1 Blockchain to be both credibly neutral in both its finances and its architecture. About The Foundation The Telos Foundation is a Decentralized Autonomous Organization established as a promotional and funding body to advance the Telos Blockchain Network and provide support to network applications. Contact Details The Team hello@telosfoundation.io Company Website https://www.telos.net/

June 07, 2022 10:21 AM Eastern Daylight Time

Video

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that the first clinical results of TRUE AVC™ acellular vascular conduit in hemodialysis access will be presented at the Vascular Access Society of the Americas (VASA) conference in Charleston, South Carolina at 11:20 am EDT on June 10, 2022. The presentation, titled “First in Human Evaluation of a Novel Biologic Regenerative Vascular Conduit for Hemodialysis Access”, will be made by Vascudyne’s medical advisor Monnie Wasse, MD, MPH, FASN, Professor of Medicine in the Division of Nephrology and Department of Internal Medicine at Rush University Medical Center. Dr. Wasse serves as Vice-Chairperson for Clinical Operations for the Department of Medicine and is also the Director of Interventional Nephrology, focused on the planning and maintenance of dialysis vascular access for patients with kidney diseases. Dr. Wasse will present 6-month results and preliminary evidence of the safety and effectiveness of the device as a conduit for hemodialysis vascular access. Vascudyne’s TRUE™ Tissue products are unique, 100% biological, and become the patient’s own living and functional tissue. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine cardiovascular devices with synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. “Dr. Wasse brings extensive experience and clinical expertise to our medical advisory board, and we are excited she is presenting the promising initial results from the TRUE AVC studies,” said Mark Stenoien, Vascudyne’s Chief Regulatory and Clinical Science Officer. Vascudyne announced in February its relocation to a high capacity GMP manufacturing facility to support TRUE AVC manufacturing through commercialization. “We are excited to share our first clinical results with our TRUE Tissue technology in hemodialysis access and have been working on developing our platform technology to address additional cardiovascular diseases” said Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “Our move to the new facility dramatically increased our GMP manufacturing space and added a dedicated cleanroom that is poised to support our ongoing TRUE AVC clinical studies all the way to commercialization,” added Dr. Syedain. TRUE AVC is not available for commercial sale. Dr. Monnie Wasse, MD, MPH, FASN Vascudyne’s Clinical Collaborators at Sanatorio Italiano in Asuncion, Paraguay Vascudyne’s TRUE AVC TM for Hemodialysis Access About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Sandy Williams, Marketing Director swilliams@vascudyne.com

June 07, 2022 09:23 AM Eastern Daylight Time

Image

ThreatModeler Announces New Patent for IaC-Assist

ThreatModeler Software, Inc

ThreatModeler, a leader in securing cloud infrastructure from design to deployment, today announced the issuance of their newest patent, which makes the IaC-Assist a proprietary technology. The patent, US Patent No. 20220004645A1, has been issued and granted as of April 26, 2022. With IaC-Assist, any user can truly shift left as it relates to implementing security within the code. Users can identify, review, and mitigate security flaws while writing the code in real-time - with simply the click of a button and without leaving their coding environment. IaC-Assist creates a more time and cost-efficient solution to the build process, saving developers the hours it would have taken to build designs and review its security. “Our patented solution, IaC-Assist, reduces threat drift from code to cloud and gives users a simple and efficient solution in truly shifting left,” said Archie Agarwal, Founder and CEO, ThreatModeler. “This patented technology is the only solution in the industry that helps you build threat models from your IDE itself and updates the threat model as you update the code. We’re excited to have these streamlined capabilities patented and available to users.” This patented technology solution is the first of its kind that helps to reduce threats from code to cloud. Users can implement the technology as a processor-executed method of generating a threat model from a code file. The system can analyze the code file, identify properties associated with the resources included in the code file, and generate a threat model based on the resources determined as a security threat. This technology addresses industry pain points by giving tools for security teams to work more collaboratively with the development organizations. Additionally, instead of adding more steps to the build and deploy process, this technology fits within the existing process and enables developers to build security within the code with the least amount of time lost. To learn more about this new patent and ThreatModeler technology, please visit here. About ThreatModeler Software, Inc. ThreatModeler Software, Inc. 's suite of products empowers DevOps to measure their threat drift from code to cloud. With a fraction of the time and cost tied to other tools, users can design, build and validate threat drift from development to deployment. Teams can instantly visualize their attack surface, understand security requirements and prioritize steps to mitigate threats. CISOs can make critical security-driven business decisions to scale their infrastructure for growth. Contact Details Clayton Murtle ThreatModeler@luminapr.com

June 07, 2022 08:00 AM Eastern Daylight Time

Healthcare

ALDERHEY@NYWHERE™ CREATING A HOSPITAL OF THE FUTURE: “A HOSPITAL WITHOUT WALLS”

New Survey Shows the Next Generation Embraces Remote Work for College to Career Transition

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

Oakland Pharmacy Inc. Partners With Comcast Business to Improve Network Management, Security and Speeds

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Telos Blockchain Sponsors Unbound Now Gala

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

ThreatModeler Announces New Patent for IaC-Assist